302 related articles for article (PubMed ID: 22894958)
21. Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis.
Rosa BR; Cunha AJLAD; Medronho RA
BMJ Open; 2019 Mar; 9(3):e019368. PubMed ID: 30872537
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico.
Arredondo JL; Villagomez Martinez SM; Concepcion Morales M; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
Vaccine; 2021 Jun; 39(25):3388-3396. PubMed ID: 33992441
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
[TBL] [Abstract][Full Text] [Related]
25. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
[TBL] [Abstract][Full Text] [Related]
26. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
27. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
[TBL] [Abstract][Full Text] [Related]
28. First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers.
Crevat D; Brion JD; Gailhardou S; Laot TM; Capeding MR
Pediatr Infect Dis J; 2015 Aug; 34(8):884-92. PubMed ID: 25966916
[TBL] [Abstract][Full Text] [Related]
29. The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review.
Agarwal R; Wahid MH; Yausep OE; Angel SH; Lokeswara AW
Acta Med Indones; 2017 Jan; 49(1):24-33. PubMed ID: 28450651
[TBL] [Abstract][Full Text] [Related]
30. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.
Harenberg A; Begue S; Mamessier A; Gimenez-Fourage S; Ching Seah C; Wei Liang A; Li Ng J; Yun Toh X; Archuleta S; Wilder-Smith A; Shek LP; Wartel-Tram A; Bouckenooghe A; Lang J; Crevat D; Caillet C; Guy B
Hum Vaccin Immunother; 2013 Nov; 9(11):2317-25. PubMed ID: 23839107
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.
López P; Lanata CF; Zambrano B; Cortés M; Andrade T; Amemiya I; Terrones C; Gil AI; Verastegui H; Marquez V; Crevat D; Jezorwski J; Noriega F
Pediatr Infect Dis J; 2016 Oct; 35(10):1140-7. PubMed ID: 27254034
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.
Hassan J; Toh TH; Sivapunniam SK; Hasim R; Ghazali NF; Sulaiman S; Koh MT; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
Pediatr Infect Dis J; 2021 Aug; 40(8):774-781. PubMed ID: 34250977
[TBL] [Abstract][Full Text] [Related]
33. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
34. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
[TBL] [Abstract][Full Text] [Related]
35. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
Dorigatti I; Aguas R; Donnelly CA; Guy B; Coudeville L; Jackson N; Saville M; Ferguson NM
Vaccine; 2015 Jul; 33(31):3746-51. PubMed ID: 26051515
[TBL] [Abstract][Full Text] [Related]
36. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
[TBL] [Abstract][Full Text] [Related]
37. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
Torresi J; Richmond PC; Heron LG; Qiao M; Marjason J; Starr-Spires L; van der Vliet D; Jin J; Wartel TA; Bouckenooghe A
J Infect Dis; 2017 Oct; 216(7):834-841. PubMed ID: 28968794
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines.
Santos J; Montellano ME; Solante R; Perreras N; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
Pediatr Infect Dis J; 2021 Sep; 40(9):856-863. PubMed ID: 34117198
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
[TBL] [Abstract][Full Text] [Related]
40. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]